報價延遲最少15分鐘:2026/04/15 09:41 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
23.56 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.29/-3.62
|
|
企業價值
2.98B
|
| 資產負債 |
|
每股賬面淨值
5.03
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
247.00M
|
|
每股收益
0.96
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies. |
